New horizons in hepatitis C antiviral therapy with direct-acting antivirals

New Protease Inhibitors for the Treatment of Chronic Hepatitis C

(2013) Shan Liu et al.   ANNALS OF INTERNAL MEDICINE

Analysis of hepatitis C virus resistance to silibininin vitroandin vivopoints to a novel mechanism involving nonstructural protein 4B

(2013) Katharina Esser-Nobis et al.   HEPATOLOGY

The antimalarial ferroquine is an inhibitor of hepatitis C virus

(2013) Thibaut Vausselin et al.   HEPATOLOGY

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

(2013) Edward J. Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

(2012) Vincenzo Summa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus

(2012) Angela M. Lam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid and sharp decline in hepatitis C virus upon monotherapy with NS3 protease inhibitor, ACH-1625

(2012) Atul Agarwal et al.   ANTIVIRAL THERAPY

Second generation direct antivirals and the way to interferon-free regimens in chronic HCV

(2012) Heather Lewis et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

The role of resistance in HCV treatment

(2012) Johannes Vermehren et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease

(2012) X. Christopher Sheng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C

(2012) Mei H. Chang et al.   CLINICAL THERAPEUTICS

TMC435 for the treatment of chronic hepatitisC

(2012) Sudeep Tanwar et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Telaprevir for the treatment of hepatitis C

(2012) Nicole Forestier et al.   EXPERT OPINION ON PHARMACOTHERAPY

Is Hepatitis Virus Resistance to Antiviral Drugs a Threat?

(2012) Jean–Michel Pawlotsky   GASTROENTEROLOGY

New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye: Table 1

(2012) Geoffrey Dusheiko et al.   GUT

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C

(2012) Calogero Cammà et al.   HEPATOLOGY

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

(2012) Jin-Hua Sun et al.   HEPATOLOGY

Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders

(2012) Enrico Galmozzi et al.   HEPATOLOGY

Antiviral strategies in hepatitis C virus infection

(2012) Christoph Sarrazin et al.   JOURNAL OF HEPATOLOGY

1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

(2012) F. Poordad et al.   JOURNAL OF HEPATOLOGY

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

(2012) Dominique Larrey et al.   JOURNAL OF HEPATOLOGY

Hepatitis C therapy in non-genotype 1 patients: the near future

(2012) C. Wartelle-Bladou et al.   JOURNAL OF VIRAL HEPATITIS

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

(2012) F. Poordad et al.   JOURNAL OF VIRAL HEPATITIS

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation

(2012) Robert J. Fontana et al.   LIVER TRANSPLANTATION

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function

(2012) Christy M. Hebner et al.   PLoS One

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein

(2012) Oscar Belda et al.   VIRUS RESEARCH

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

(2012) Keith P. Romano et al.   PLoS Pathogens

New opportunities in anti-hepatitis C virus drug discovery: Targeting NS4B

(2011) Roopa Rai et al.   ANTIVIRAL RESEARCH

Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase

(2011) Leen Delang et al.   ANTIVIRAL RESEARCH

Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity

(2011) X. Christopher Sheng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Mixing and Matching Drugs: What Makes Sense?

(2011) Tania M. Welzel et al.   Clinics in Liver Disease

Second-wave Protease Inhibitors: Choosing an Heir

(2011) Sandra Ciesek et al.   Clinics in Liver Disease

The NS5A Replication Complex Inhibitors: Difference Makers?

(2011) Robert G. Gish et al.   Clinics in Liver Disease

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

(2010) P. W. White et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

New Insights into Structure and Replication of the Hepatitis C Virus and Clinical Implications

(2010) Marion Poenisch et al.   SEMINARS IN LIVER DISEASE

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

(2009) T.-I Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

(2009) N. J. Liverton et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture

(2009) Immacolata Conte et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

Identification of Hepatitis C Virus NS5A Inhibitors

(2009) J. A. Lemm et al.   JOURNAL OF VIROLOGY

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

(2008) S. D. Seiwert et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

(2008) A. Y. M. Howe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

(2008) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

(2008) Norman M. Kneteman et al.   HEPATOLOGY

Treatment predictors of a sustained virologic response in hepatitis B and C

(2008) Annika Kau et al.   JOURNAL OF HEPATOLOGY

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis

(2008) Shirit Einav et al.   NATURE BIOTECHNOLOGY